Nanjing Sike Pharmaceutical Co., Ltd. clinical trials
Acquired by Luye Pharma Group Ltd., 2007 · source ↗
The registry lists 3 studies whose lead sponsor is Nanjing Sike Pharmaceutical Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 15, 2009.
Before and after it joined Luye Pharma Group Ltd.
- First submitted before Nanjing Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- 0
- First submitted after Nanjing Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- 3
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Nanjing Sike Pharmaceutical Co., Ltd.3 studies
Something wrong with this grouping? Tell us on the Luye Pharma Group Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Luye Pharma Group Ltd. studies →
- Clinical Study of Liposomal Paclitaxel in Chinese PatientsStatus unknownNCT00881101Phase 1
Sponsor listed in the registry: Nanjing Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric CarcinomaStatus unknownNCT00639522Phase 1
Sponsor listed in the registry: Nanjing Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric CarcinomaStatus unknownNCT00881816Phase 1
Sponsor listed in the registry: Nanjing Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.